Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice. 2011

Ju-Young Moon, and Mitsuo Tanimoto, and Tomohito Gohda, and Shinji Hagiwara, and Takahiko Yamazaki, and Ikko Ohara, and Maki Murakoshi, and Tatsuya Aoki, and Yuji Ishikawa, and Sang-Ho Lee, and Kyung-Hwan Jeong, and Tae-Won Lee, and Chun-Gyoo Ihm, and Sung Jig Lim, and Yasuhiko Tomino
Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.

ANG-(1-7) is associated with vasodilation and nitric oxide synthase stimulation. However, the role of ANG-(1-7) in type 2 diabetes mellitus is unknown. In this study, we examined the hypothesis that ANG-(1-7) attenuates ANG II-induced reactive oxygen species stress (ROS)-mediated injury in type 2 diabetic nephropathy of KK-A(y)/Ta mice. KK-A(y)/Ta mice were divided into four groups: 1) a control group; 2) ANG II infusion group; 3) ANG II+ANG-(1-7) coinfusion group; and 4) ANG II+ANG-(1-7)+d-Ala(7)-ANG-(1-7) (A779) coinfusion group. In addition, primary mesangial cells were cultured and then stimulated with 25 mM glucose with or without ANG II, ANG-(1-7), and A779. The ANG II+ANG-(1-7) coinfusion group showed a lower urinary albumin/creatinine ratio increase than the ANG II group. ANG-(1-7) attenuated ANG II-mediated NAD(P)H oxidase activation and ROS production in diabetic glomeruli and mesangial cells. ANG II-induced NF-κB and MAPK signaling activation was also attenuated by ANG-(1-7) in the mesangial cells. These findings were related to improved mesangial expansion and to fibronectin and transforming growth factor-β1 production in response to ANG II and suggest that ANG-(1-7) may attenuate ANG II-stimulated ROS-mediated injury in type 2 diabetic nephropathy. The ACE2-ANG-(1-7)-Mas receptor axis should be investigated as a novel target for treatment of type 2 diabetic nephropathy.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D000803 Angiotensin I A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Ju-Young Moon, and Mitsuo Tanimoto, and Tomohito Gohda, and Shinji Hagiwara, and Takahiko Yamazaki, and Ikko Ohara, and Maki Murakoshi, and Tatsuya Aoki, and Yuji Ishikawa, and Sang-Ho Lee, and Kyung-Hwan Jeong, and Tae-Won Lee, and Chun-Gyoo Ihm, and Sung Jig Lim, and Yasuhiko Tomino
January 2003, Journal of nephrology,
Ju-Young Moon, and Mitsuo Tanimoto, and Tomohito Gohda, and Shinji Hagiwara, and Takahiko Yamazaki, and Ikko Ohara, and Maki Murakoshi, and Tatsuya Aoki, and Yuji Ishikawa, and Sang-Ho Lee, and Kyung-Hwan Jeong, and Tae-Won Lee, and Chun-Gyoo Ihm, and Sung Jig Lim, and Yasuhiko Tomino
January 2011, Nephron. Experimental nephrology,
Ju-Young Moon, and Mitsuo Tanimoto, and Tomohito Gohda, and Shinji Hagiwara, and Takahiko Yamazaki, and Ikko Ohara, and Maki Murakoshi, and Tatsuya Aoki, and Yuji Ishikawa, and Sang-Ho Lee, and Kyung-Hwan Jeong, and Tae-Won Lee, and Chun-Gyoo Ihm, and Sung Jig Lim, and Yasuhiko Tomino
November 2004, Metabolism: clinical and experimental,
Ju-Young Moon, and Mitsuo Tanimoto, and Tomohito Gohda, and Shinji Hagiwara, and Takahiko Yamazaki, and Ikko Ohara, and Maki Murakoshi, and Tatsuya Aoki, and Yuji Ishikawa, and Sang-Ho Lee, and Kyung-Hwan Jeong, and Tae-Won Lee, and Chun-Gyoo Ihm, and Sung Jig Lim, and Yasuhiko Tomino
February 2007, Metabolism: clinical and experimental,
Ju-Young Moon, and Mitsuo Tanimoto, and Tomohito Gohda, and Shinji Hagiwara, and Takahiko Yamazaki, and Ikko Ohara, and Maki Murakoshi, and Tatsuya Aoki, and Yuji Ishikawa, and Sang-Ho Lee, and Kyung-Hwan Jeong, and Tae-Won Lee, and Chun-Gyoo Ihm, and Sung Jig Lim, and Yasuhiko Tomino
May 2008, Metabolism: clinical and experimental,
Ju-Young Moon, and Mitsuo Tanimoto, and Tomohito Gohda, and Shinji Hagiwara, and Takahiko Yamazaki, and Ikko Ohara, and Maki Murakoshi, and Tatsuya Aoki, and Yuji Ishikawa, and Sang-Ho Lee, and Kyung-Hwan Jeong, and Tae-Won Lee, and Chun-Gyoo Ihm, and Sung Jig Lim, and Yasuhiko Tomino
March 2004, Journal of hypertension,
Ju-Young Moon, and Mitsuo Tanimoto, and Tomohito Gohda, and Shinji Hagiwara, and Takahiko Yamazaki, and Ikko Ohara, and Maki Murakoshi, and Tatsuya Aoki, and Yuji Ishikawa, and Sang-Ho Lee, and Kyung-Hwan Jeong, and Tae-Won Lee, and Chun-Gyoo Ihm, and Sung Jig Lim, and Yasuhiko Tomino
December 2006, International journal of biomedical science : IJBS,
Ju-Young Moon, and Mitsuo Tanimoto, and Tomohito Gohda, and Shinji Hagiwara, and Takahiko Yamazaki, and Ikko Ohara, and Maki Murakoshi, and Tatsuya Aoki, and Yuji Ishikawa, and Sang-Ho Lee, and Kyung-Hwan Jeong, and Tae-Won Lee, and Chun-Gyoo Ihm, and Sung Jig Lim, and Yasuhiko Tomino
April 2012, Regulatory peptides,
Ju-Young Moon, and Mitsuo Tanimoto, and Tomohito Gohda, and Shinji Hagiwara, and Takahiko Yamazaki, and Ikko Ohara, and Maki Murakoshi, and Tatsuya Aoki, and Yuji Ishikawa, and Sang-Ho Lee, and Kyung-Hwan Jeong, and Tae-Won Lee, and Chun-Gyoo Ihm, and Sung Jig Lim, and Yasuhiko Tomino
August 2003, Biochemical and biophysical research communications,
Ju-Young Moon, and Mitsuo Tanimoto, and Tomohito Gohda, and Shinji Hagiwara, and Takahiko Yamazaki, and Ikko Ohara, and Maki Murakoshi, and Tatsuya Aoki, and Yuji Ishikawa, and Sang-Ho Lee, and Kyung-Hwan Jeong, and Tae-Won Lee, and Chun-Gyoo Ihm, and Sung Jig Lim, and Yasuhiko Tomino
January 2016, Laboratory investigation; a journal of technical methods and pathology,
Copied contents to your clipboard!